Additional therapy for cholesterol lowering in ezetimibe-treated, statin-intolerant patients in clinical practice: results from an internal audit of a university lipid clinic

Current Medical Research and Opinion

Volumn 32, Issue 10, 2016, Pages 1633-1638

  Cicero, Arrigo F G ^a   Morbini, Martino ^a   Bove, Marilisa ^a   D’Addato, Sergio ^a   Fogacci, Federica ^a   Rosticci, Martina ^a   Borghi, Claudio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Ezetimibe; Hypercholesterolemia; Nutraceuticals; Statin intolerance

Indexed keywords

BERBERINE; EZETIMIBE; FENOFIBRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISPAGULA; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHYTOSTEROL; ROSUVASTATIN; UBIDECARENONE;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE CONTROL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MYALGIA; PATIENT SELECTION; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; RETROSPECTIVE STUDY;

EID: 84973621840     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1080/03007995.2016.1190326     Document Type: Article

References (46)

1. Cholesterol Treatment Trialists’ (CTT) Collaboration; J.Fulcher, R.O’Connell, M.Voysey,. Efficacy and safety of LDL-lowering therapy among men and women:meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 2015;385:1397-405
2. H.L.Lv, D.M.Jin, M.Liu,. Long-term efficacy and safety of statin treatment beyond six years:a meta-analysis of randomized controlled trials with extended follow-up. Pharmacol Res 2014;81:64-73
3. D.Rosenbaum, J.Dallongeville, P.Sabouret, E.Bruckert Discontinuation of statin therapy due to muscular side effects:a survey in real life. Nutr Metab Cardiovasc Dis 2013;23:871-5
4. G.Chodick, V.Shalev, Y.Gerber,. Long-term persistence with statin treatment in a not-for-profit health maintenance organization:a population-based retrospective cohort study in Israel. Clin Ther 2008;30:2167-79
5. A.Alfirevic, D.Neely, J.Armitage,. Phenotype standardization for statin-induced myotoxicity. Clin Pharmacol Ther 2014;96:470-6
6. D.J.Graham, J.A.Staffa, D.Shatin,. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004;292:2585-90
7. G.B.Mancini, A.Y.Tashakkor, S.Baker,. Diagnosis, prevention, and management of statin adverse effects and intolerance:Canadian Working Group Consensus update. Can J Cardiol 2013;29:1553-68
8. T.A.Jacobson NLA Task Force on Statin Safety – 2014 update. J Clin Lipidol 2014;8(Suppl 3):S1-S4
9. Z.Ahmad Statin intolerance. Am J Cardiol 2014;113:1765-71
10. I.J.Riphagen, E.van der Veer, F.A.Muskiet, M.J.DeJongste Myopathy during statin therapy in the daily practice of an outpatient cardiology clinic:prevalence, predictors and relation with vitamin D. Curr Med Res Opin 2012;28:1247-52
11. E.S.Stroes, P.D.Thompson, A.Corsini,.; European Atherosclerosis Society Consensus Panel. Statin-associated muscle symptoms:impact on statin therapy – European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J 2015;36:1012-22
12. M.Banach, M.Rizzo, P.P.Toth,. Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch Med Sci 2015;11:1-23
13. H.Naci, J.Brugts, T.Ades Comparative tolerability and harms of individual statins:a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials. Circ Cardiovasc Qual Outcomes 2013;6:390-9
14. E.P.Navarese, A.Buffon, F.Andreotti,. Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus. Am J Cardiol 2013;111:1123-30
15. N.A.Sattar, H.Ginsberg, K.Ray,. The use of statins in people at risk of developing diabetes mellitus:evidence and guidance for clinical practice. Atheroscler Suppl 2014;15:1-15
16. H.Joosten, S.T.Visser, M.E.van Eersel,. Statin use and cognitive function:population-based observational study with long-term follow-up. PLoS One 2014;9:e115755
17. K.Richardson, M.Schoen, B.French,. Statins and cognitive function:a systematic review. Ann Intern Med 2013;159:688-97
18. C.H.Rojas-Fernandez, J.C.Cameron Is statin-associated cognitive impairment clinically relevant? A narrative review and clinical recommendations. Ann Pharmacother 2012;46:549-57
19. W.M.Mampuya, D.Frid, M.Rocco,. Treatment strategies in patients with statin intolerance:the Cleveland Clinic experience. Am Heart J 2013;166:597-603
20. A.J.Keating, K.B.Campbell, J.R.Guyton Intermittent nondaily dosing strategies in patients with previous statin-induced myopathy. Ann Pharmacother 2013;47:398-404
21. H.E.Bays, P.B.Moore, M.A.Drehobl,.; Ezetimibe Study Group. Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia:pooled analysis of two phase II studies. Clin Ther 2001;23:1209-30
22. C.Gagné, H.E.Bays, S.R.Weiss,.; Ezetimibe Study Group. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002;90:1084-91
23. A.F.Cicero, A.Ferroni, S.Ertek Tolerability and safety of commonly used dietary supplements and nutraceuticals with lipid-lowering effects. Expert Opin Drug Saf 2012;11:753-66
24. European Association for Cardiovascular Prevention & Rehabilitation; Z.Reiner, A.L.Catapano, G.De Backer,.; ESC Committee for Practice Guidelines (CPG) 2008–2010 and 2010–2012 Committees. ESC/EAS Guidelines for the management of dyslipidaemias:the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769-818
25. S.P.Kennedy, G.P.Barnas, M.J.Schmidt,. Efficacy and tolerability of once-weekly rosuvastatin in patients with previous statin intolerance. J Clin Lipidol 2011;5:308-15
26. V.G.Athyros, K.Tziomalos, A.I.Kakafika,. Effectiveness of ezetimibe alone or in combination with twice a week atorvastatin (10 mg) for statin intolerant high-risk patients. Am J Cardiol 2008;101:483-5
27. C.Meek, A.S.Wierzbicki, C.Jewkes,. Daily and intermittent rosuvastatin 5 mg therapy in statin intolerant patients:an observational study. Curr Med Res Opin 2012;28:371-8
28. H.Nakamura, K.Arakawa, H.Itakura,.; MEGA Study Group. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study):a prospective randomised controlled trial. Lancet 2006;368:1155-63
29. Z.Lu, W.Kou, B.Du,.; Chinese Coronary Secondary Prevention Study Group. Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. Am J Cardiol 2008;101:1689-93
30. M.C.Gerards, R.J.Terlou, H.Yu, C.H.Koks, V.E.Gerdes Traditional Chinese lipid-lowering agent red yeast rice results in significant LDL reduction but safety is uncertain - a systematic review and meta-analysis. Atherosclerosis 2015;240:415-23
31. R.Y.Gordon, T.Cooperman, W.Obermeyer, D.J.Becker Marked variability of monacolin levels in commercial red yeast rice products:buyer beware! Arch Intern Med 2010;170:1722-7
32. G.Marazzi, L.Caciotti, F.Pelliccia,. Long-term effects of nutraceuticals (berberine, red yeast rice, policosanol) in elderly hypercholesterolemic patients. Adv Ther 2011;28:1105-13
33. A.F.Cicero, G.Derosa, C.Borghi Red yeast rice and statin-intolerant patients. Am J Cardiol 2010;105:1504
34. S.S.Kumar, K.A.Lahey, A.Day, S.A.LaHaye Comparison of the efficacy of administering a combination of ezetimibe plus fenofibrate versus atorvastatin monotherapy in the treatment of dyslipidemia. Lipids Health Dis 2009;8:56
35. J.Lan, Y.Zhao, F.Dong, Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. J Ethnopharmacol 2015;161:69-81
36. G.Derosa, P.Maffioli, A.F.Cicero Berberine on metabolic and cardiovascular risk factors:an analysis from preclinical evidences to clinical trials. Expert Opin Biol Ther 2012;12:1113-24
37. J.F.Brensike, R.I.Levy, S.F.Kelsey,. Effects of therapy with cholestyramine on progression of coronary arteriosclerosis:results of the NHLBI Type II Coronary Intervention Study. Circulation 1984;69:313-24
38. S.Abourbih, K.B.Filion, L.Joseph,. Effect of fibrates on lipid profiles and cardiovascular outcomes:a systematic review. Am J Med 2009;122:962.e1-8
39. C.P.Cannon, M.A.Blazing, R.P.Giugliano,.; IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015;372:2387-97
40. J.G.Robinson, M.Farnier, M.Krempf,.; ODYSSEY Long Term Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015;372:1489-99
41. M.S.Sabatine, R.P.Giugliano, S.D.Wiviott,.; Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015;372:1500-9
42. M.A.De Vera, V.Bhole, L.C.Burns, D.Lacaille Impact of statin adherence on cardiovascular disease and mortality outcomes:a systematic review. Br J Clin Pharmacol 2014;78:684-98
43. J.F.Slejko, M.Ho, H.D.Anderson,. Adherence to statins in primary prevention:yearly adherence changes and outcomes. J Manag Care Pharm 2014;20:51-7
44. M.Banach, C.Serban, A.Sahebkar,.; Lipid and Blood Pressure Meta-analysis Collaboration Group. Effects of coenzyme Q10 on statin-induced myopathy:a meta-analysis of randomized controlled trials. Mayo Clin Proc 2015;90:24-34
45. B.A.Taylor, L.Lorson, C.M.White, P.D.Thompson A randomized trial of coenzyme Q10 in patients with confirmed statin myopathy. Atherosclerosis 2015;238:329-35
46. H.T.Cho, L.Salvia-Trujillo, J.Kim,. Droplet size and composition of nutraceutical nanoemulsions influences bioavailability of long chain fatty acids and Coenzyme Q10. Food Chem 2014;156:117-22